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Abstract: Leukemia is a type of hematopoietic stem/progenitor cell malignancy characterized by the
accumulation of immature cells in the blood and bone marrow. Treatment strategies mainly rely on
the administration of chemotherapeutic agents, which, unfortunately, are known for their high toxicity
and side effects. The concept of targeted therapy as magic bullet was introduced by Paul Erlich about
100 years ago, to inspire new therapies able to tackle the disadvantages of chemotherapeutic agents.
Currently, nanoparticles are considered viable options in the treatment of different types of cancer,
including leukemia. The main advantages associated with the use of these nanocarriers summarized
as follows: i) they may be designed to target leukemic cells selectively; ii) they invariably enhance
bioavailability and blood circulation half-life; iii) their mode of action is expected to reduce side
effects. FDA approval of many nanocarriers for treatment of relapsed or refractory leukemia and the
desired results extend their application in clinics. In the present review, different types of nanocarriers,
their capability in targeting leukemic cells, and the latest preclinical and clinical data are discussed.
Keywords: nanocarrier; nanosystem; nanoparticle; liposome; leukemia; AML; ALL; CLL; CML;
targeted therapy
1. Introduction
Leukemia is a heterogeneous disease resulting from the transformation of hematopoietic
stem/progenitor cells and it is the 10th most prevalent cause of cancer in the world [1,2]. Leukemia
is divided into the lymphoid and myeloid lineages, and the acute or chronic phase is determined by
the maturity stage of the cells [3]. For many years, chemotherapeutic agents have been considered as
the choice for the treatment of leukemia but their efficacy, due to the appearance and development
of chemoresistance and unwanted side effects, are compromised [4]. Furthermore, low solubility
and bioavailability of some drugs and a need to increase the selectivity of the treatment implied
marked modifications of treatment strategies. It has been shown that, by using conventional treatment,
one can eradicate the bulk disease population whereas some resistant cells and also leukemic stem
cells (LSCs) persist even after the treatment [5,6]. To tackle these problems and due to the increase
in our knowledge about the pathogenesis of leukemia, many targeting-based therapies, ranging
from antibodies to inhibitors of signaling pathways, have been introduced [7,8]. Simultaneously,
the outstanding development in the field of nanomaterials for cancer treatment pave the way to new
therapeutic routs aimed at pursuing targeted therapy, reduction of toxicity, controlled release, delivery
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of therapeutic RNAs, and a desirable carrier for combinatorial treatment [9]. All of these features led
to the Food and Drug Administration (FDA) approval of many nanoparticles for the treatment of
relapsed or refractory leukemia.
In this review article, different types of nanoparticles, their characteristics, and their efficiency in
targeting leukemic cells are surveyed, and with the aim of delineating the future of nanomedicine-based
therapy. At the end, we discuss clinically approved nanoparticles as the new means of treatment
in leukemia.
2. Nanoparticles as Drug Delivery Systems
The concept of nanotechnology was first introduced by the physicist Robert Feynman in 1959
during a talk he delivered at Caltech University [10]. Since then, nanotechnology enormously grew
in a number of fields, including physics, biology, chemistry, medicine, electronics, and information
technology, and it is currently part of our everyday life. The advent of nanotechnology in the medical
field, giving rise to the term nanomedicine, dates back to the 1990s [11], even if several nanosystems,
now applied for drug delivery, were designed and developed previously in the 1960s [12]. The term
‘nanosystem’ refers to a system having a size comprised between 1 and 1000 nm [11]. They are
mostly designed for drug delivery (triggered or non-triggered), imaging, regenerative, and gene
therapy purposes. The great advantages of nanosystems are their ability to deliver a high amount of
an agent (drug, chemical, or biological product) at the desired site, generally increasing its stability
and its blood circulation lifetime while decreasing its side effects (for instance to systemic effects
associated to chemotherapeutic drugs) [13,14]. Moreover, according to the composition of the system,
nanotechnologies allow to encapsulate and deliver hydrophobic molecules, generally difficult to
be freely administered, increasing their solubility and biocompatibility [15,16]. Last but not least,
the possibilities of surface modification of nanosystems are enormous, paving the way to the targeting
of selected receptors. This aspect is of paramount importance in the era of personalized medicine and
will be more thoroughly explored in the next paragraph.
To be eligible for in vivo applications, nanosystems must be composed of materials that are
biocompatible, non-toxic, and biodegradable [17]. Moreover, they should be stable after administration
and, in view of possible clinical translation, their preparation as easily up-scaled for manufacturing
with a high control over their physicochemical properties [14]. Most of the nano-therapeutic products
currently approved by the FDA are meant for parenteral administration; only a few preparations
have been designed for topic or oral administration. The first nanosystem approved was AmBisome®
(Gilead Sciences, Inc., Foster City, California, US), a liposomal formulation of amphotericin B for
the treatment of fungal infections [18]. The advantage of amphotericin B encapsulation into high
transition temperature phospholipids and cholesterol improved drug’s efficiency and reduced its
systemic toxicity [19]. Nowadays, the majority of nanosystems on the market address cancer treatment
(Table 1), but other applications include mental illness, anemia, and inflammatory diseases such as
rheumatoid arthritis, inflammatory bowel disease, asthma, multiple sclerosis, and diabetes [20]. In the
following subsections, an overview of the main nanotherapeutic systems currently available will
be given.
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Table 1. FDA and European Medicines Agency (EMA)-approved nano-based formulations for cancer
related therapy (ref: ema.europa.eu; drugs.com; fda.gov)
Brand Name Nanotechnology Drug Indications Approval
Abraxane Albumin-Nanoparticles Paclitaxel
Breast cancer 2005




citrate Kaposi’s sarcoma 1996









[poly(lactic-co-glycolic acid)] Leuprolide acetate Prostate cancer 2002
Marqibo® Liposome
Vincristine
sulfate Acute lymphoblastic leukemia 2012
Mepact® Liposomal Mifamurtide Osteosarcoma 2009
Myocet® Liposome Doxorubicin Metastatic breast cancer 2000
Nanotherm® Iron oxide NPs n.a. Glioblastoma 2010
Onivyde® Liposome Irinotecan Pancreatic cancer 2015
2.1. Liposomes
Liposomes were first discovered by Bangham et al. [12]. Since then, the research in the field of
these nanosystems developed enormously, and they are now considered to be the most successful
drug-carrier system known to date [21]. Liposomes are bilayered vesicles, composed of an aqueous
core surrounded by one (small unilamellar vesicles, SUVs; or large unilamellar vesicles, LUVs) or
more (multilamellar vesicles, MLVs) bilayers of phospholipids [22]. Phospholipids are amphiphilic
molecules composed of a hydrophilic head and one or two hydrophobic tails. These molecules
spontaneously tend to re-arrange in an aqueous environment to form a structure similar to that of
biological membranes [21]. Liposomes are extremely versatile nanocarriers (Figure 1) as they can
load both hydrophilic and hydrophobic molecules. Hydrophilic molecules are generally encapsulated
into the aqueous core, while hydrophobic ones are usually entrapped into the bilayer, among the
hydrophobic tails [16]. When the drug is loaded into these systems, it is not bioavailable. Therefore,
the strong advantages of drug encapsulation into liposomes resides in (i) its protection against naturally
occurring phenomena, such as enzymatic degradation and immunologic and chemical inactivation;
(ii) prevention of its metabolization before reaching target tissues; (iii) reduced exposure of healthy
tissue to the drug; and (iv) increased blood circulation life time [23–25]. Taken together, all these effects
generally contribute to achieving an increased therapeutic index [26].
The composition of phospholipids can vary considerably, affecting liposome properties. The type
of phospholipids used, for example, can influence the liposomal surface charge. Neutral liposomes are
generally less stable and tend to aggregate; moreover, they do not interact much with cells, thus releasing
their cargo in the extracellular environment [27]. Among commonly used neutral phospholipids, we can
cite dioleoyl phosphatidylethanolamine (DOPE), dioleoyl phosphatidylcholine (DOPC), or dipalmitoyl
phosphatidylcholine (DPPC). Anionic liposomes are generally composed of negatively charged lipids,
such as dimyristoyl phosphatidylglycerol (DMPG) and dipalmitoyl phosphatidylglycerol (DPPG).
The development of negatively charged liposomes for parenteral administration, however, met with
some drawbacks basically associated to their interaction with biological systems, with consequent drug
release, toxic effects, and fast opsonization by complement and other circulating proteins, followed by
liposome uptake by the immune system cells [28]. Cationic liposomes, instead, were first described by
Felgner et al. in 1978 [29], and are currently designed mainly for gene delivery purposes, due to the
occurrence of stable electrostatic interaction between negatively charged nucleic acids and positively
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charged phospholipids [30]. Among phospholipids employed to obtain cationic liposomes there are 1,
2-dioleoyl-3-trimethylammonium-propane (DOTAP), dioleoylphosphatidyl ethanolamine (DOPE),
dimethyldioctadecylammonium bromide, N-[1-(2,3-dioleoyloxy) propyl]-N,N,N-trimethyl-ammonium
methyl sulfate and oleic acid (OA). The addition of cholesterol into the phospholipid bilayer can decrease
the permeability of the liposome membrane and increase its in vitro/in vivo stability, thanks to the dense
phospholipid-packing effect exerted by this hydrophobic molecule [31]. Another component often
employed for liposome formulation are pegylated phospholipids: lipids modified with polyethylene
glycol (PEG). PEG is a non-toxic and non-ionic hydrophilic polymer that confers to liposomes higher
stability and extended blood circulation time, due to the reduced uptake by immune system cells [32].
It acts as a steric barrier, hindering the interactions between the nanosystem and serum protein
that are involved in recognition of the carriers by the mononuclear phagocyte system. This steric
stabilization was reported to increase blood half-life of liposomes from 2 h up to 24 h in rodents (mice
and rats) and as high as 45 h in humans, depending on the particle size and the characteristics of the
coating polymer [23]. Finally, specific phospholipids or molecules can be included in the liposomal
formulation to achieve triggered release under certain conditions (e.g., temperature, pH, enzymes, light,
ultrasounds). Temperature triggered drug release is based on the phase transition temperature (Tm) of
phospholipids. Tm is defined as the temperature at which a transition occurs from an ordered gel phase
to a disordered fluid phase [33]; during this transition, the liposomal payload is generally released,
due to the loosening of the tightly packaging of the phospholipid bilayer. The first thermosensitive
liposomes developed were mainly composed of phosphatidylcholines, bearing a Tm in the range
of mild hyperthermia (40–43 ◦C) [34]. While, ThermoDoxTM, a liposomal formulation containing
doxorubicin currently in a clinical trial for the treatment of hepatocellular carcinoma (clinicaltrials.org
identifier: NCT00617981), exploits the lysolipid thermally sensitive liposome technology to encapsulate
doxorubicin and release it selectively at 41.3 ◦C, thanks to pore formation into the membrane [35,36].
Thus, the release can be easily localized only in artificially heated regions (e.g., tumor region).
2.2. Micelles
Micelles are another type of biocompatible nanosystems, with a size comprised between 5 and
100 nm. They are composed of a monolayer of amphiphilic molecules that spontaneously tend
to self-assemble in aqueous environments at a definite concentration, known as critical micelle
concentration (CMC). These amphiphilic molecules are generally fatty acids, salts of fatty acid (soaps),
phospholipids, or other similar amphiphilic compounds [37]. Micelles present either a hydrophobic
core, exposing outside the hydrophilic polar heads, or a hydrophilic core, exposing outside the
hydrophobic tails (inverted micelles) (Figure 2) [38]. They usually encapsulate hydrophobic drugs into
the hydrophobic core, whereas hydrophilic drugs can be adsorbed or chemically linked to the outer
shell [39]. The first method of encapsulation is generally less stable, as these structures can rapidly
de-assemble after intravenous injection, due to both a dilution effect and interactions with surfactant
proteins. To overcome this drawback, many strategies have been proposed, among which are the
inclusion of a crystalline copolymer and a copolymer with a lower critical micellar concentration in the
formulation, or the crosslinking of the core and/or shell regions [40]. The delivery of anti-cancer drugs
within biocompatible micelles in comparison to free drug administration resulted in reduced systemic
toxicity and increased drug solubility as well as site-specific tumor accumulation [41].
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Figure 1. Schematic representation of the different types of liposomal drug delivery systems.
(A) Conventional liposome: liposome composed of a lipid bilayer of anionic, cationic or neutral
phospholipids and cholesterol. Drugs can be incorporated both in the bilayer (hydrophobic drugs)
and in the aqueous core (hydrophilic drugs). (B) PEGylated liposomes: lipid bilayer endowed with
a PEGylated phospholipid to make the nanosystem stealth and sterically stable. (C) Ligand-targeted
liposome—Liposomes can be used for specific targeting by attaching ligands (e.g., antibodies, peptides,
and carbohydrates) to its surface or to the terminal end of the attached PEG chains. (D) Theranostic
liposome—A lipid bilayer bearing at the same time an imaging and a therapeutic agent. A targeting
vector can also be introduced. Reproduced with permission from [23], licensed under CC BY.
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Figure 2. Schematic representation of (A) normal micelles and (B) inverted micelles. Adapted from [38]
(published by MDPI), licensed under CC BY.
2.3. Polymeric Nanoparticles
Polymeric nanoparticles are either solid nanospheres or nanocapsules displaying a size
of 1–1000 nm. They can be composed of either synthetic polymers, such as poly(lactide),
poly(lactide-co-glycolide), and poly(ε-caprolactone), or natural polymers like chit san, alginate,
elatin, and albumin [42]. These polymers must be biocompatible and biodegradable. Drugs ca
either be dispers d within the polymer matrix r di ectly conj ated to the polym molecule.
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Drug release can occur in different ways: diffusion, swelling of the polymer matrix, or polymer
erosion, and degradation [43]. In general, synthetic polymers allow for sustained drug release, within
a period of days to weeks, while natural polymers are more easily and rapidly degraded. The most
diffuse biodegradable polymer used for the preparation of nanoparticles is poly(lactic-co-glycolic acid)
(PLGA) [44]. PLGA is an FDA approved copolymer of poly lactic acid (PLA) and poly glycolic acid
(PGA), displaying a wide range of erosion times and tunable mechanical properties [45]. According to
the molar ratio of PLA and PGA used for polymerization, different forms of PLGA can be obtained.
PLGA Nanoparticles have been widely used in preclinical investigations for the encapsulation and
delivery of various anticancer drugs, however, so far, no anticancer PLGA formulations have been
approved by FDA.
Poly(ε-caprolactone) is another FDA approved polymer used to prepare nanoparticles. It is
obtained from the monomer ε-caprolactone and, in comparison to PLGA, display a slower
degradation time both in vitro and in vivo, thus being more suitable for long-term delivery systems.
Many poly(ε-caprolactone) Nanoparticles have been synthesized for cancer therapy displaying very
high encapsulation efficiency values [46,47].
Chitosan is a natural biodegradable, biocompatible polymer obtained by the partial N-deacetylation
of chitin. It can be easily functionalized, resulting in a broad portfolio of possible applications. It has
reduced toxicity and has been often used for the preparation of nanoparticles containing anticancer
drugs [48,49]. Nanoparticles prepared with chitosan and chitosan derivatives, in fact, typically
possess a positive surface charge and mucoadhesive properties that facilitate their adhesion to mucous
membranes and the release of the drug payload in a sustained release manner [50]. Moreover, due to
their positive charge, they can be used as non-viral vectors for gene therapy. Chitosan based polymeric
nanoparticles are generally designed for non parenteral administration.
Another type of polymeric nanoparticles are nanogels, also known as hydrogels nanoparticles,
with a size generally comprised between 20 and 200 nm and a large surface area [50]. In the last decade,
much research has been devoted to the development of these nanosystems. Nanogels can be obtained
by physical or chemical cross-linking of synthetic hydrophilic polymers or biopolymers. Physical
cross-linking, being non-covalent, is considered to be less stable, thus requiring additional stability
assays before in vitro/in vivo experiments. The porous network resulting from the cross-linking allows
for high drug entrapment efficiency. The advantages of using nanogels in comparison to the free drug
are enhanced drug stability, prolonged blood circulation time, and the possibility to respond to specific
stimuli to obtain drug release (pH, magnetic field, light, ionic content, and temperature) [51]. Moreover,
their high water content and living tissue-like physical properties ensure high biocompatibility.
Nanogels meant as anticancer drug delivery systems have been recently designed [52,53].
2.4. Solid Lipid Nanoparticles (SLNs)
Solid lipid nanoparticles (SLNs) are systems with a size of 50–1000 nm, composed of lipids that are
solid at body temperature (fatty acids, steroids, waxes, monoglycerides, diglycerides or triglycerides),
surfactants, as stabilizers, and sometimes co-surfactants. SLNs combine the advantages of emulsions
and liposomes with those of polymeric nanoparticles (like protection of incorporated drugs from
degradation, controlled release, excellent tolerability), while simultaneously avoiding some of their
disadvantages such as in vivo stability problems [54]. Additionally, SLNs can overcome several
physiological barriers that hinder drug delivery to tumors and are also able to escape multidrug
resistance mechanisms, characteristic of cancer cells. Hydrophobic drugs can be easily trapped in the
lipidic matrix, while hydrophilic drugs must be chemically conjugated to the lipidic components or to
pegylated phospholipids that are sometimes added in order to obtain steric hindrance and enhance SLNs
blood circulation time [55]. Potential disadvantages of SLNs are their insufficient drug loading capacity
(around 25–50% in comparison to the lipid matrix) and the possible accidental drug expulsion during
long-term storage [56]. These drawbacks are generally caused by the formation of the crystal solid state
of the lipids into the matrix, depending on the selection and relative proportion of the components,
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as well as on the preparation method. Due to possible post-production polymorphic transition of the
crystals, in fact, drug expulsion and particle instability can occur. To increase drug-loading capacity,
lipids forming non-ordered crystals are then preferred (mono-, di-, triglycerides, with different chain
lengths). Moreover, to facilitate drug encapsulation and boost the in vivo drug release rate, the addition
of one or more lipids liquid at room temperature (like oleic acid, for example) to SLNs formulation can
be envisaged, obtaining the so-called nanostructured lipid carriers (NLCs) [57]. Depending on the
amount of liquid lipid, its insertion will give rise to amorphous or partially crystalline solid matrices.
Another critical aspect in the formulation of SLNs and NLCs is the choice of surfactant molecules,
which should be compatible with the employed lipids. Among the amphiphilic molecules used as
surfactants, we can cite monoacylglycerides of long-chain fatty acids, phospholipids, some esters,
poloxamers, and polisorbates. Co-surfactant, like bile salts such as taurodeoxycholate, or alcohols such
as butanol or ethanol, can be added to further increase the stability of SLNs. The use of SLNs as vehicle
for anticancer drugs has been widely explored and resulted in greater cytotoxic capacity than that of
free drugs, enhanced drug bioavailability, and reduced systemic side effects [58,59]. Finally, it is worth
mentioning that, in view of eventual clinical translation, large-scale production of SLNs is technically
and economically feasible.
2.5. Inorganic Nanoparticles
Inorganic nanoparticles are systems composed mainly of inorganic compounds and pure metals.
The most investigated ones are quantum dots, gold, iron oxide, and silica nanoparticles (Figure 3).
Gold nanoparticles are characterized by low toxicity, peculiar optical and electrical properties, potential
biodegradability, and considerable surface modifiability, thus representing a highly feasible material
for treating malignant tumors. They have a size of 1–150 nm and are generally composed of a gold
atom core that can be functionalized by the addition of a monolayer of various moieties containing
a thiol group [60]. A PEG coating can also be added to these nanoparticles to make them stealth and
increase their blood half-life. They are used in preclinical investigations and clinical trials as drug
delivery carriers [61], in photodynamic therapy for the treatment of cancer or imaging purposes [62].
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Figure 3. Main types of inorganic nanoparticles: (A) silica nanoparticles, (B) iron oxide nanoparticles,
(C) gold nanoparticles, (D) quantum DOTs. Adapted from [63].
Iron oxide nanoparticles can display ferromagnetic or superparamagnetic (preferred in the medical
field) properties. Their size ranges from a few nm to microns. They have been widely investigated
mainly for magnetic resonance imaging (MRI) purposes and the treatment of anemia, obtaining the
approval of the FDA. Moreover, they can be exploited to induce local heat enhancement (hyperthermia)
when submitted to an alternative magnetic field in order to selectively kill cancer cells [64]. Iron oxide
nanoparticles are considered biocompatible, stable, and biodegradable systems. Their usage for
drug delivery purposes has been investigated only in recent years. In general, they are composed of
an inorganic core made of magnetite (Fe3O4) or maghemite (γ-Fe2O3) surrounded by an (in)organic
coating that must ensure stability and stealth in biological media. Moreover, their surface can be
modified in order to make the nanoparticles responsive to a specific stimulus (change in pH, temperature,
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or redox state) and trigger drug release [65]. The great advantage of iron oxide nanoparticles, in
comparison to other types of nanocarriers, is the possibility to guide drug release magnetically.
Silica nanoparticles are highly biocompatible, biodegradable, and chemically stable nanosystems
(size of 10–10,000 nm), displaying an easily tunable mesoporous structure (2–50 nm pore size).
Their solid framework, composed of Si-O bonds, is extremely resistant to degradation or external
stresses. Thanks to their high surface to volume ratio, they display elevated drug loading capacity as
well homogeneous drug loading. Moreover, various functional groups can be easily attached to the
particles in order to target them to a particular site or to make them responsive to a specific stimulus,
in order to trigger drug release [66]. The major drawback of these systems resides in their hemolytic
effect, due to the favorable interaction between their silanol groups and the surface of the phospholipids
of red blood cell membranes [67]. Since their first introduction by Vallet-Regi and co-workers in the
early 2000s, many silica nanoparticles have been designed for cancer drug delivery purposes [68].
Finally, even if used mainly for imaging purposes, also quantum dots (QDs) should be mentioned
among inorganic nanoparticles used for cancer therapy. QDs are small nanoparticles (2–50 nm in
diameter) consisting of semiconducting material (like Cd, Se, Zn, Te, Hg, and Pb), displaying unique
optical and electronic properties [39]. The primary issue for their possible clinical translation is their
toxicity, associated with the presence of heavy metals and their colloidal instability [69].
3. Targeted Cancer Therapy: Advantages in Comparison to Conventional Treatments
The idea of targeted therapy was introduced by Paul Erlich in the first 1900s, with the so-called
“magic bullet concept”: drugs should go straight to their intended cell targets, thus efficiently killing
pathogens, while being harmless in healthy tissues [70]. This concept initially referred mainly to
infectious diseases was then extended to cancer treatment. The first breakthrough in cancer targeted
therapy dates back to World War II when the injection of mustin, the prototype of nitrogen mustards
(cytotoxic anti-cancer agents), to a patient with non-Hodgkin lymphoma caused a robust anti-tumor
effect [71]. Erlich thus assumed that small molecules could be useful in the treatment of cancer. Later on,
in 1948, S. Farber, now known as the “father of modern chemotherapy”, observed that folic acid yielded
a proliferative effect on cancer cells when administered to children suffering from acute lymphoblastic
leukemia (ALL). According to this observation, he synthesized antagonists of folic acid that proved to
be effective in the treatment of this pathology [72] and became the mainstays of leukemia chemotherapy.
In the 1970s–1980s, the second wave of cancer-targeted therapeutic drugs was proposed. During these
years, various small target molecules were designed in order to hit specific mutations identified as
driving forces of cancer progression. Among plenty of agents developed to target crucial effectors
involved in cell proliferation, invasion, metastasis, angiogenesis, and apoptosis [73], imatinib was
synthesized [74]. Imatinib, a tyrosine kinase inhibitor, now considered as a milestone drug, proved
to be effective in the treatment of chronic myeloid leukemia (CML) [75]. One step further was made
with the development of Sunitinib, a multi-targeted chemotherapeutic. This drug was developed,
starting from the consideration of cancer as a multi-factorial disease. Sunitinib targets simultaneously
all receptors for platelet-derived growth factors (PDGF-Rs) and vascular endothelial growth factor
receptors (VEGFRs), which play a role in both tumor angiogenesis and tumor cell proliferation, and also
CD117, a tyrosine kinase receptor that (when improperly activated by mutation) drives the majority of
gastrointestinal stromal cell tumors receptors namely CD114, CD135, and RET [76]. Finally, the latest
breakthrough has been applied for the production of monoclonal antibodies, as shown by Georges
Köhler and César Milstein in 1975 [77,78]. Erlich already predicted that “antibodies are in a way magic
bullets that identify their target themselves without harming the organism” [73]. However, the first
murine antibodies administered to humans presented, many drawbacks mainly linked to immune
reactions and reduced ability to induce immune effector mechanisms [79]. In the years that followed,
a number of chimeric and humanized antibodies able to attack cancer cells with various strategies,
such as antibody-dependent cellular toxicity, complement-dependent cytotoxicity, modulation of
signal transduction, and immunomodulation, were developed [80,81]. The first successful monoclonal
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antibody approved by the FDA (in 1998) for the treatment of breast cancer was trastuzumab, an antibody
able to specifically target ERBB2 (also known as HER2) receptor, overexpressed in breast and ovarian
cancer [82]. In the same years, Rituximab was also approved by the FDA. Rituximab is a genetically
engineered chimeric mouse-human antibody that binds to the transmembrane antigen CD20, involved
in B-cell non-Hodgkin lymphoma. Since its initial approval in 1997, it has improved outcomes in all
B-cell malignancies [83]. Nowadays, many drug-antibody conjugates are under development, in order
to merge the advantages of monoclonal antibodies with chemotherapeutic drugs, while at the same
time eluding drug resistance mechanisms. Taken together, all these discoveries have contributed to
substantial progress in cancer therapy. One step further has been made by conjugating these targeting
strategies to the use of nanosystems, already in the clinical practice since the 1990s. As illustrated in
the previous paragraph, nanosystems have the advantage of protecting the encapsulated drug from
degradation, bringing a high payload of a drug at the site of interest, increasing its blood circulation
time, and delivering it more specifically to cancer cells, through passive or active targeting.
3.1. Passive Targeting
The term ‘passive targeting’ refers to the accumulation of a drug or a drug-carrier system into
a specific organ or pathological tissues via biological mechanisms, such as RES (reticuloendothelial
system) or EPR (enhanced permeability and retention) effects [84]. The reticuloendothelial system,
also known as the mononuclear phagocyte system, consists of cells descending from the monocytes,
which can perform phagocytosis of foreign materials and particles. It is part of the body’s defense
mechanisms. If the nanoparticles are not appropriately modified, they can be rapidly taken up and
retained into the major reticuloendothelial organs (liver and spleen, mainly). At present, the most
promising strategies to limit RES uptake consist of reducing particle size (particles with a diameter
below 35 nm seems to be less prone to RES uptake) and in sterically stabilizing the nanocarriers
utilizing PEG-lipids [85].
The EPR effect, first described in 1986 by Matsumura and Maeda, is based on anatomical differences
between healthy and tumor vasculature. The fast and disordered tumor growing process lead to the
development of vasculature with a quite abnormal architecture, characterized by leaky blood vessels,
with gaps as large as 600–800 nm, and poor lymphatic drainage [86]. This allows the extravasation of
macromolecules through these gaps into the extravascular space and their accumulation inside solid
tumor tissues (Figure 4) [87]. The EPR effect results in a substantial increase in tumor drug storage in
comparison to healthy organs and in dramatically enhanced, usually 10-fold or higher, tumor drug
accumulation, when it is delivered by a nanoparticle rather than as a free drug. [88]. It should be
noted that the EPR effect can vary considerably as it is affected by various factors, such as tumor size,
tumor perfusion, variation in endothelial gap size (ranging from one to hundreds of nanometers)
and nanoparticle characteristics (e.g., size, surface charge, shape, etc.). Moreover, it should be noted
that passive targeting cannot be used as a strategy to deliver Nanoparticles to treat hematological
malignancies (i.e., leukemia and lymphoma) and metastatic lesions, as under these circumstances
EPR effect does not play any role [89]. In hematologic malignancies, in fact, tumor cells are free in
circulation, thus requiring specific active targeting. However, confined tumor sites, such as the bone
marrow and/or lymphoid tissues, in which the EPR effect can be exploited are also present [90].
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3.2. Active Targeting
The term ‘active targeting’ refers to the conjugation of targeting moieties on the surface of
nanocarriers for the crossing of biological barriers, specific tumor homing, increased retention at
the target site, and uptake by target cells. When designing actively targeted nanoparticles some
factors must be considered in order to maximize the targeting efficiency. First, the targeted antigen
or receptor should be expressed solely on tumor cells and not on healthy cells to minimize or avoids
off-target effects of the active therapeutic agents on healthy tissues. Second, they should be expressed
homogeneously on the targeted tumor cells. Third, the recognition between the receptor and the
targeting moiety should not be prevented in blood circulation, for example, due to protein corona
adsorption onto the nanocarrier [91]. Finally, to improve treatment efficiency, it is vital that not only the
receptor-targeting ligand recognition takes place but also that the internalization of the nanocarriers
occurs [88]. Targeting moieties include peptides, protein domains, antibodies, aptamers, and small
molecules, such as folate or growth factors.
The major advantages of using small natural molecules as targeting ligands reside in their stability,
ease, and density of conjugation at the surface of nanoparticles; potential low cost; lower molecular
weight; and lower immunogenicity than antibodies. However, some of these ligands, such as folate,
transferrin, or carbohydrates (like lactose, galactose, galactosamine, mannose, glucose, trehalose,
and hyaluronic acid), naturally display quite high concentration in human body as they are supplied
by food intake, thus competing with the targeted nanocarrier in receptor binding and consequently
reducing specific drug delivery [92,93].
Polypeptide-based moieties—including peptides, protein domains, and antibodies—are among
the most diffuse targeting ligands. Antibodies are highly specific ligands; they can be used as both
therapeutic and targeting agents [94]. Their big size, while favoring the specific interaction with the
targeted receptors, limits their density on the nanoparticle surface as well as can induce immunogenicity
and considerable RES uptake. In the last decades, many nanoparticles functionalized with antibody
have been designed, among which are immunoliposomes, composed of liposomes entrapping one
or more anticancer drugs, functionalized with monoclonal antibodies, like anti-HER2 or anti-EGFR
antibodies [95,96]. Smaller antibodies, known as affibodies, can also be used as targeting ligands.
Affibodies are engineered, robust, high-affinity proteins designed to bind a large number of target
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proteins or peptides, mimicking monoclonal antibodies. In contrast to antibodies that have the
Fc-portion, however, they lack half-life extension and effector function modules [97].
Peptides are defined as linear or cyclic amino acid sequences with less than 50 residues [98].
In comparison to proteins, peptides display a series of advantages, such as the ease and higher
density of conjugation to nanocarrier surface, higher stability, reduced immune reaction, lower cost
of manufacturing, and enhanced feasibility of large-scale production. However, the binding
specificity is limited in comparison to that of antibodies [99]. The most studied tripeptide motif is
arginylglycylaspartic acid (RGD). It can specifically bind αvβ3 and αvβ5 integrin receptors, which are
overexpressed on both tumor endothelial cells and cancer cells [100].
Aptamers, instead, are small single-stranded nucleic acids that fold into a well-defined
three-dimensional structure. They can bind to a variety of targets with high affinity and specificity and
inhibit their biological functions. The advantages of aptamers as targeting moieties in comparison to
antibodies are their reduced size, high in vivo stability, non-immunogenicity, and limited toxicity [101].
At the same time, however, their successful employment in clinics is still challenging because of their
short blood half-life, due to degradation by serum nucleases and rapid renal clearance. Moreover,
the aptamer-receptor binding is highly dependent on their three-dimensional structure, which can be
influenced by surrounding environmental conditions [102].
Even if the portfolio of available targeting ligands is extremely wide and can be specifically
tailored to each disease, the real power of targeting nanomedicine is still under debate. A recent
meta-analysis of pre-clinical data on nanoparticle-based delivery platforms for malignant tumors
published over the past ten years reported that only an average of 0.9% of the injected dose of active
targeted nanocarriers reaches the target tumors [103]. This value seems to be extremely low, however,
it is already two or three times more than what is obtained with the free drug and almost 1.5-times
more than passive-targeted systems (0.9% vs. 0.6%). In relative terms, this represents a substantial
increase in delivery efficiency and establishes the advantage of nanoparticles for tumor-targeted
drug delivery. However, in order to further increase this percentage values, some approaches can
be explored. As tumors are generally extremely heterogeneous targeting only a single cell-surface
receptor can result in partial tumor response, which in most cases is followed by a resistant tumor
relapse and mortality. The development of a novel class of nanoparticles with versatile targeting
moieties or bearing different targeted ligands simultaneously has been proposed [89].
4. Nanosystems in the Treatment of Myeloid Malignancies
Acute myeloid leukemia (AML), the most common form of leukemia in adults, is characterized by
abnormal proliferation, block of differentiation, and infiltration of immature cells into blood and bone
marrow [104]. Treatment of AML, consisting of continuous infusion of cytarabine and anthracycline in
the 7 + 3 regimen, has not been changed from past decades [105]. In this case, we are facing an overall
survival (OS) of about 40% in younger patients and inferior results for patients who are older than 60
years of age [106]. The addition of new FDA approved compounds such as Midostaurin, and Giltritinib
for targeting Fms-related tyrosine kinase 3 (FLT3) mutated AML, Enasidenib, and Ivosidenib for
isocitrate dehydrogenase 1 and 2 mutated AML, and also Venetoclax as BCL2 inhibitor, has been
carried out to ameliorate the outcome [107,108].
Patients with therapy-related AML (t-AML) as the result of previous chemotherapy or
radiation [109] and patients with the history of myelodysplastic related changes (AML-MRC) [110]
account for 10–20% of the AML cases. Albeit these patients have been removed from many clinical
trials due to their inferior prognosis, a nano-based approach called CPX-351 was developed in 2017
for the treatment of these subgroups [33]. CPX-351 is a liposomal formulation of combinatorial
therapy composed of cytarabine and daunorubicin in a fixed 5:1 molar ratio. The liposome membrane
is comprised of distearoylphosphatidylcholine, distearoylphosphatidylglycerol, and cholesterol in
a 7:2:1 molar ratio. Encapsulation of the above drugs into the liposome has several advantages over
conventional therapy, such as increment of blood circulation half-life, reduction of toxicity, and above
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all, maintaining the molar ratio, among the administered drugs which guarantees the synergistic effect
and may circumvent antagonistic effect [111,112]. In a randomized clinical trial phase 2, the efficacy of
CPX-351 and conventional 7 + 3 regimens in newly diagnosed t-AML and AML-MRC was compared.
While the target was OS, using CPX-351 notably increased median OS compared to 7 + 3 regimens (9.56
months compared with 5.95 months). Meanwhile, attaining a higher complete remission in patients
who received CPX-351 demonstrates the power of this approach [113].
FLT-3, which accounts for 30% of AML cases, is associated with poor prognosis. This tyrosine
kinase receptor promotes survival, proliferation, and differentiation blockade in leukemic cells by
activating downstream signaling pathways [114,115]. Jiang et al. used polyamidoamine dendrimers
conjugated with FLT-3 ligand loaded with microRNA(miR)-150 as a tumor suppressor. This system,
by selectively targeting FLT-3 mutated cells, exhibited a profound anti-tumor effect both in vitro and
in vivo and negated off-target interactions [116]. It has been shown that miR-29b is downregulated
in AML and is considered as a tumor suppressor microRNA [117]. In one study, targeted delivery
of miR-29b via lipopolyplex nanoparticle conjugated transferrin led to the downregulation of some
genes participating in leukemogenesis and brought about a higher survival rate in the mouse model
of AML [118]. Some studies demonstrated that nucleolin, a multifunctional protein involved in
metabolism and gene regulation, has a higher expression on the surface of the leukemic cells [119].
Deng et al., in order to exploit this feature, designed a gold nanoparticle loaded with doxorubicin
conjugated with an anti-nucleolin aptamer called AS1411 and anti-miR-221 as an oncogenic miR.
This multifunctional nanoparticle revealed a high efficiency in targeting resistant leukemic cells [120].
In another subtype of AML, acute promyelocytic leukemia (APL), the preferred type of treatment is
germane to using all-trans-retinoic acid (ATRA) in combination with arsenic trioxide or chemotherapy
agents [121]. In recent years, a novel synthetic retinoid called ST1926 has been produced to target APL
and also other forms of leukemia [122,123]. ST1926 displayed lower toxicity and is regarded as a more
potent agent in inducing apoptosis and controlling cell growth. However, due to lower bioavailability
and fast excretion, El-Houjeiri et al., loaded ST1926 in polystyrene-b-poly ethylene diblock copolymer.
The drug-loaded NP appeared to have enormous potential in reducing leukemic cell proliferation
(in vitro) and diminishing tumor burden and enhancement of survival in a mouse model of AML [124].
CD33 is commonly expressed in leukemic cells compared to healthy hematopoietic stem cells it
represents a good alternative for targeted therapy. Many experiments using anti-CD33 antibody and
conjugation with liposome or lanthanide oxyfluoride nanoparticle reported an effective way to target
CD33 expressing leukemic cells [125,126].
Although most of the conventional drugs and designed nanoparticles are dependent on the
elimination of the bulk disease population, a small and rare population called leukemic stem cells
(LSC) may be able to resist the therapy and may relapse after a while [127,128]. These leukemic
stem cells, after facing ineffective therapies, evolve and change their characteristics and make a new
population of LSC [129]. In such circumstances, eradication of LSC has to be tackled with alternative
approaches. The population of LSC in AML is heterogeneous, and the expression of CD markers such
as CD44, CD47, CD93, CD96, CD123, CLL-1, TIM-3, etc., is variable from patient to patient. Moreover,
some of these markers, such as CD44 and CD47, are also expressed on normal stem/progenitor cells,
thus finding specific markers of AML LSC using various techniques such as flow cytometry and cell
surface capturing technology for targeted therapy by nanoparticle seems practical [127,130].
In the study devoted to target AML LSC, Lin et al. produced nano-micelles loaded with
daunorubicin and conjugated it with a CLL-1 targeting peptide. They reported higher toxicity on
leukemic stem cells and lower serial transplantation capability in mice as the representation of the
self-renewal feature of leukemic stem cells [131]. Parthenolide (PTL) also exerted an inhibitory
effect on leukemic stem/progenitor cells through the upregulation of P53 as a tumor suppressor and
downregulation of NF-kβ as a pro-survival transcription factor. However, due to low bioavailability
and poor solubility, micelle and nanoparticle loaded PTL appeared good systems to eliminate leukemic
stem cells selectively [132,133].
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In most cases, the nanomedicine in leukemia has been used to solve the problem of lower
bioavailability and higher toxicity, but it can be used in several ways to improve the treatment in
AML. Namely, i) using nanocarriers loaded with different agents for combination therapy to increase
drugs half-life and to keep the different drugs molar ratios fixed; ii) targeting selectively a resistant
subpopulation, which may differ from patient to patient; iii) using nanosystems concomitantly with
conventional therapy to eradicate bulk disease population and leukemic stem cells simultaneously.
CML is a hematopoietic stem cell malignancy that results from a translocation between the
Abelson gene (ABL1) on chromosome 9 and break point cluster region (BCR) gene on chromosome 22.
The encoded protein governs the disease by activating downstream signaling pathways. However,
absent effective therapy second mutation transforms the chronic phase to the acute phase, which is
associated with a higher proliferation rate and impairment of differentiation [134,135]. Treatment of
CML is based on applying different generation of tyrosine kinase inhibitors (TKIs) such as imatinib,
nilotinib, and dasatinib. In half of the CML patients who achieve a deep molecular response,
therapy can be halted without leukemic recurrence, a term called treatment-free remission (TFR).
However, it appears possible to increase the number of patients who achieve TFR, including the
case of resistance due to domain mutations and the presence of CML LSCs, which are insensitive
to TKIs treatment [134,136]. In this context, Liu et al. encapsulated homoharringtonine, a drug for
patients resistant to TKIs, into PEGylated liposome, and they demonstrated comparable safety and
lower toxicity as opposed to the bare drug [137]. In another study, loading bortezomib into liposome
conjugated to transferrin significantly targeted CML resistant cells to doxorubicin and made them more
sensitive to this agent [138]. Jyotsana et al. designed a liposome loaded with siRNA against BCR-ABL1
and claimed that this system could decrease the disease burden in the mouse model of CML [139].
As many markers and molecular participants in the pathogenesis of CML have been discovered, it is
expected they may open up an opportunity to develop a nanomedicine-based therapy to optimize the
treatment strategy.
5. Nanosystems in the Treatment of Lymphoid Malignancies
ALL is the most common form of cancer in children with an incidence rate of 1.6 per 100,000
persons [140]. ALL follows a bimodal distribution with the main peak in children and the second peak
in patients who are older than 50 years of age [141]. While some genetic abnormalities such as down
syndrome, Fanconi anemia, or even environmental factors augment the risk of ALL, in most cases,
it is regarded as a de novo disease [142]. The treatment strategy is based on employing chemotherapy
agents such as vincristine for induction, consolidation, and maintenance. By using conventional
therapies, the cure rate in children is satisfactory with a 5-year OS of about 90%, while in older
patients, the response rate falls off and is between 30–40% [143]. The occurrence of patients who are
resistant to first induction therapy and patients who relapse at any stage of the treatment is the major
obstacle of the effective treatment and salvage therapy based on CAR T-cells, and targeted therapy by
antibodies against CD19 (such as coltuximab ravtansin), CD20 (such as rituximab), and CD22 (such as
inotuzumab ozogamicin) appears to be the best viable option [140]. Vincristine, as a chemotherapy
drug, has been employed in different steps of ALL treatment and even as salvage therapy. However,
the administration of this agent is accompanied by toxicities such as neuropathy, which increases in
a dose-dependent manner [144,145]. To deal with this problem, vincristine sulfate liposome injection
(VSLI) was developed. This liposomal formulation increased the biodistribution and half-life of
vincristine sulfate and allowed for a higher dose of intensification compared to bare vincristine. In the
clinical trial phase 2, patients in the second or greater relapse treated weakly with 2.25 mg/m2 of VSLI
achieved complete remission of 20% and an overall response rate of 35% [146,147].
Spleen tyrosine kinase (SYK) proceeds through the activation of B cell receptor (BCR) or pre-B
cell receptor in B-ALL. It works as a signal transducer and by triggering downstream signaling
pathways such as PI3K and NF-kβ acts as a critical element in BCR signaling [148]. Studies reported
that, by blocking SYK, cell growth was hampered and apoptosis were induced in the leukemic cells.
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Uckun et al. demonstrated higher expression of SYK in B-ALL in early relapse and reported that the
encapsulation of C61, an inhibitor of SYK phosphorylation, into liposome had a potent anti-leukemic
activity [149]. Further study revealed that the combination of this approach with low dose total body
irradiation (TBI) could remarkably deplete refractory B-ALL clone and leading to higher OS compared
to TBI and C61-liposome alone [150].
CD19 is a transmembrane protein that is expressed by B cell lineage and is a co-receptor of BCR.
CD19 in a complex with BCR interacts with downstream tyrosine kinase proteins and has a role in the
enhancement of proliferation in leukemic cells. Also, a higher internalization feature after attachment
of the antibody makes it a suitable antigen for targeting [151,152]. Another study demonstrated that
the conjugation of an antibody against CD19 tagged with C61-liposome displayed higher potency in
the eradication of B-ALL and in the reduction of clonogenic activity in vivo due to the lower off-target
effect [153]. Conjugating anti-CD19 to norcantharidin loaded liposome also displayed a high specificity
and toxicity against CD19 positive cells [154].
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in western countries
with an incidence rate of 4–5 per 100,000 inhabitants. The median age at diagnosis is around 70 years
and is recognized by the uncontrolled proliferation of CD5+ B lymphocytes in the blood, bone marrow,
lymph node, and spleen [155,156]. As the frontline treatment, chlorambucil, a chemotherapy
agent, has been used for several decades, and the development of a combination therapy based
on anti-CD20 (rituximab), purine analogue such as fludarabine and cyclophosphamide has improved
the treatment [155,157]. It has been verified that higher BCL2 protein in CLL patients increases the
resistant to therapy, and like any other form of leukemia, venetoclax as BCL2 inhibitor offered a choice
for the treatment [158]. The combination of venetoclax and rituximab in relapsed or refractory CLL
patients showed a prominent efficiency, and 2-year progression-free survival rates were 84.9% [159].
G3139 is antisense to the first six codons of bcl2 mRNA. Preclinical and clinical studies revealed
that G3139 significantly induces apoptosis and reduces chemosensitivity in many cancers, including
CLL [160]. A recent study confirmed that targeting the delivery of G3139 with immunoliposome
conjugated rituximab had a therapeutic benefit [161]. In another study, Chiang at al. produced miR-29b
loaded immunoliposomes and conjugated this system with an antibody against Tyrosine-protein kinase
transmembrane receptor (ROR1). Since ROR1 is mainly expressed by CLL leukemic cells, using this
strategy seems a good approach for selective targeting [162]. In summary, studies based on the use of
nanomedicine-based therapy in ALL and CLL proved the efficiency of the approach by diminishing
side effects and boosting the efficiency of the treatment.
6. Clinical Trials
Clinical trials of nanosized systems currently ongoing for the treatment of myeloid and lymphoid
malignancies are manifold (Table 2). These trials concern the administration of nanoscaled agents either
alone or in combination with other drugs or biological agents. The most diffuse formulation is the
CPX-351, also known as Vyxeos® (Jazz Pharmaceuticals, Dublin, Ireland), a liposomal-encapsulated
combination of cytarabine and daunorubicin, approved by the Food and Drug Administration (FDA)
in 2017 for the treatment of newly diagnosed t-AML or AML-MRC [33]. Cytarabine, also known
as cytosine arabinoside (ara-C), is a pyrimidine nucleoside analogue that inhibits the synthesis of
DNA, acting on the S phase of the cell cycle. It also has antiviral and immunosuppressant properties.
Daunorubicin instead, is an anthracycline topoisomerase inhibitor. Based on the assumption that
different drugs administered together can act antagonistically or synergistically depending on the
proportional amount of each agent [111], various preclinical studies have been carried out to find
the best performing ratio between cytarabine and daunorubicin. Finally, the optimal molar ratio
of the two agents encapsulated into the CPX-351 liposomal system was found out to be cytarabine:
daunorubicin 5:1 [163]. In the numerous clinical trials in which CPX-351 is currently involved, it is
administered either alone or in combination with other drugs/biological agents. An example is the
combination of CPX-351 and gemtuzumab ozogamicin (NCT03672539). Gemtuzumab ozogamicin is
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an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic
derivative of calicheamicin. Free calicheamicin exerts its effect into the nucleus, where it binds DNA
and induces double strand breaks, leading to cell cycle arrest and apoptosis. In principle, stem cells
and non-hematopoietic cells should not be affected by this agent due to lack of CD33 expression [164].
The clinical trial aims at evaluating if giving CPX-351 and gemtuzumab ozogamicin may work better in
treating patients with AML, compared to giving only one of these therapies alone. Another formula in
a clinical trial is the combination of CPX-351 and ruxolitinib for the treatment of patients with secondary
AML (NCT03878199). Ruxolitinib is a potent selective ATP-competitive inhibitor of Janus-associated
kinases (JAK1 and JAK2), with potential antineoplastic and immunomodulating activities. More in
detail, this drug may lead to a reduction in inflammation and an inhibition of cellular proliferation
due to a decrease in the amount of circulating inflammatory cytokines [165]. Giving ruxolitinib
and CPX-351 in combination may work better in treating patients with secondary acute myeloid
leukemia compared to CPX-351 alone. Another drug currently under evaluation in combination with
CPX-351 is Palbociclib, a CDK4/6 inhibitor already approved for the treatment of breast cancer [166].
Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
The purpose of the NCT03844997 clinical trial is to test the safety and efficacy of the combination of
palbociclib and CPX-351 in patients with acute myeloid leukemia. Other drugs/agent in phase testing
in combination with CPX-351 are Venetoclax, a BCL-2 inhibitor with antineoplastic activity [167],
or Enasidenib, an inhibitor of isocitrate dehydrogenase 2 (IDH2), approved in the United States for the
treatment of adult patients with mutant-IDH2 relapsed or refractory (R/R) AML [168].
Another nanosized system currently in clinical trials for various types of leukemia, including acute
myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia
(CML), is DepoCyt® (Pacira Pharmaceuticals, Parsippany-Troy Hills, New Jersey, US) [169]. DepoCyt®,
also known as Ara-C, is a liposomal formulation containing 10 mg/mL of cytarabine, approved in
2007 by FDA to treat lymphomatous meningitis, a life-threatening complication of lymphoma. It is
administered directly intratechally to overcome blood–brain barrier crossing issues, and in comparison
to free cytarabine it results in a significantly extended half-life, prolonged exposure to the therapy,
and more uniform distribution. The liposomal formulation of DepoCyt® exploits the DepoFoam™ drug
delivery technology [170]. DepoFoam™ consists of microscopic spheroids (3–30 µm) with granular
structure and single-layered lipid particles composed of a honeycomb of numerous nonconcentric
internal aqueous chambers containing the bounded drug (Figure 5) [26].
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Figure 5. Spheroid and granular structure of a DepoFoam™ particle. Reproduced with permission
from [26] (published by MDPI), licened under CC BY.
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Table 2. Ongoing clinical trials involving nanosized systems administered alone or in combination with other drugs or biological agents for the treatment of various
myeloid and lymphoid malignancies. 1 Trial ID refers to Clinicaltrials.gov ID.
NANOSYSTEM ENCAPSULATED DRUG SINGLE/COMBINATION DISEASE PHASE
FIRST/
LAST POSTED NOTES REF TRIAL ID
1
Liposome Annamycin Single AML Phase I/II 2017/2019 [Gil et al., 2019] NCT03315039






Lymphoma Phase II 2015–2019 [Jurczak et al., 2015] NCT02393157
Liposome Daunorubicin-Cytarabine(CPX-351, Vyxeos®) Single Refractory AML Phase II 2019 [Mayer et al., Chen 2018 et al.] NCT04049539




Phase II 2018/2019 [Mayer et al., Chen 2018 et al.] NCT03575325







Phase II 2018/2019 [Mayer et al., Chen 2018 et al.,Baron et al.] NCT03672539
Liposome Daunorubicin-Cytarabine(CPX-351, Vyxeos®) Palbociclib AML Phase I/II 2019
[Mayer et al., Chen 2018 et al.,
Winer et al., 2019] NCT03844997
Liposome Daunorubicin-Cytarabine(CPX-351, Vyxeos®) Ruxolitinib AML, ALL Phase I/II 2019
[Mayer et al., Chen 2018 et al.,
Eghtedar et al., 2012] NCT03878199




[Mayer et al., Chen 2018 et al.,
Massimino et al., 2018] NCT04038437
Liposome Daunorubicin-Cytarabine(CPX-351, Vyxeos®) Venetoclax AML Phase II 2018/2019
[Mayer et al., Chen 2018 et al.,





AML Phase I 2019 [Mayer et al., Chen 2018 et al.,Massimino et al., 2018]] NCT04075747
Liposome Grb2 AntisenseOligonucleotide (BP1001) Dasatinib AML, CML Phase I/II 2016–2019
[Thomas et al., 2018; Ohanian
et al., 2018] NCT02923986
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Table 2. Cont.
NANOSYSTEM ENCAPSULATED DRUG SINGLE/COMBINATION DISEASE PHASE
FIRST/






Phase II 2018 [Huang et al. 2019] NCT03776279
Liposome Vincristine Venetoclax ALL Phase I/II 2018–2019 [Pathak et al., 2014] NCT03504644
























ALL Phase I 2016–2019 [Shah et al., 2016] NCT02879643
Liposome Vincristine sulfate(Marquibo®)
Inotuzumab
Ozogamicin ALL Phase I/II 2019






Lymphoma Phase I 2014–2019 [Shah et al., 2016] NCT02257242
Nanoparticle AZD2811(Barasertib) Azacitidine AML Phase I/II 2017–2019 [Floc’h et al., 2017] NCT03217838
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Each particle contains various aqueous chambers, separated from the adjacent ones by bilayer
membranes composed of lipids and phospholipids (Cholesterol: Triolein: DOPC: DPPG in 11:1:7:1
molar ratio) [171]. Upon administration of the particles, DepoFoamTM technology releases the drug
over a period of hours to weeks following erosion and/or reorganization of the lipid membranes. In the
clinical trials here reported DepoCyt® is tested in combination with either Rituximab (NCT01859819)
or Obinutuzumab or Ifosfamide, Carboplatin, Etoposide (ICE) (NCT02393157). Rituximab is a chimeric
monoclonal antibody that modulates the CD20 receptor, an antigen found on the surface of normal
and malignant B cells, thereby inducing antibody-dependent cytotoxicity, complement-dependent
cytotoxicity (CDCC), and apoptosis. It was the first monoclonal antibody approved in 1997, for the
treatment of cancer. It has been tested in combination with chemotherapy for the treatment of various
hematological malignancies, as a synergistic effect was expected [172]. Obinutuzumab is another
monoclonal antibody directed against CD20, but differently from Rituxumab, it is a type II monoclonal
antibody working primarily by inducing direct cell death and antibody-dependent cell-mediated
cytotoxicity [173]. ICE chemotherapy, instead, refers to a therapeutic regimen including Ifosfamide,
an alkylating antineoplastic agent, Carboplatin, a platinum-based antineoplastic drug, and Etoposide,
a topoisomerase inhibitor, used in the salvage treatment of relapsed or refractory non-Hodgkin’s
lymphoma and Hodgkin lymphoma. In the clinical trial in question ICE regimen has been associated
with Obinutuzumab, while DepoCyt® has been administered for both prophylaxis and treatment of
CNS disease in order to improve the clinical outcome.
An innovative nanosized formulation, currently tested as a single agent administration for the
treatment of AML, is the liposomal annamycin (NCT03315039). Annamycin is a new generation
anthracycline that circumvents multidrug-resistance transporters, including p-glycoprotein, and has
little to no cardiac toxicity [174]. This drug targets topoisomerase II, causing strand breaks in DNA.
Its encapsulation into bilamellar liposomes composed of DMPC and DMPG in a 7:3 molar ratio results
in higher entrapment of the drug and increased delivery of the drug to the tumor [89].
Marquibo® (Spectrum Pharmaceuticals, Henderson, Nevada, USA), a liposomal formulation of
Vincristine Sulfate, was developed in order to prolong the drug plasma circulation in comparison to
free Vincristine [175]. It is composed of 0.16 mg/mL of Vincristine entrapped in an aqueous interior
core of sphingomyelin/cholesterol liposomes called optisomes (sphingomyelin:cholesterol molar ratio
is 60:40) [175]. The lipidic nature of these components, together with the small diameter of the
resulting nanoparticles (around 100 nm), result in reduced protein binding and consequent prolonged
half-life time. Vincristine is an antitumor vinca alkaloid, whose mechanism of action is related to the
inhibition of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at
the metaphase stage. FDA has approved it for the treatment of relapsed ALL in adults. However,
the clinical trial NCT02337478, focused on how well vincristine sulfate liposome works in treating
patients with AML that has returned after a period of improvement or has not responded to previous
treatment, was stopped early due to futility. Other studies, still ongoing, concern the combination
of Marquibo® with various agents. Among them, we can cite Venetoclax, a BCL-2 inhibitor with
antineoplastic activity, Rituximab, and Bendamustine, a bifunctional mechlorethamine derivative with
alkylator and antimetabolite activities: its metabolites alkylate and crosslink macromolecules, resulting
in DNA, RNA, and protein synthesis inhibition, and, subsequently, apoptosis. Another promising
association under evaluation is the administration of Marquibo® together with inotuzumab ozogamicin
(NCT03851081). Inotuzumab ozogamicin is a humanized monoclonal antibody against CD22 antigen
conjugated to a cytotoxic derivative of calicheamicin, approved in several countries—including in the
USA, EU, and Japan—as monotherapy for the treatment of adults with relapsed/refractory B-ALL.
This construct allows the specific delivery of the cytotoxic drug to CD22 positive B cells. Giving
inotuzumab ozogamicin and vincristine sulfate liposome together may work better in treating patients
with CD22+ B-ALL compared to giving inotuzumab ozogamicin or vincristine sulfate liposome alone.
Other possible drug/agent associations to Marquibo® are reported in Table 2.
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An extremely original nanosystem is BP1001, a liposome-incorporated antisense
oligodeoxynucleotide that blocks the growth factor receptor-bound protein 2 (Grb2) expression [176,177].
Inhibition of Grb2 used by oncogenic tyrosine kinases for signal transduction is expected to suppress
the activation of mitogen-activated protein kinase (MAPK) 1 and MAPK3 (ERK2 and ERK1) and
inhibit leukemia progression. In the clinical trial NCT02923986, BP1001 is administered in association
with Dasatinib, an orally bioavailable synthetic small molecule inhibitor of protein kinases, used to
treat CML. Researchers hope that the combination of BP1001 and Dasatinib will provide a benefit to
leukemia affected patients.
A newly developed liposomal formulation containing mitoxantrone hydrochloride is also under
evaluation as a single agent administration for the treatment of Relapsed or Refractory Peripheral
T-cell and NK/T-cell lymphoma [178]. Mitoxantrone is a synthetic anthracenedione anticancer drug,
which is effective on lymphoma, leukemia, and other solid tumors. Its mechanism of action lies in the
intercalation into DNA, causing crosslinks and strand breaks, interference with RNA and inhibition
of topoisomerase II. It is cytotoxic both for proliferating and non-proliferating cells. Mitoxantrone
encapsulation into liposomes has been proven to prolong its blood half-life time, improving safety and
efficacy [179]. The membrane of these small unilamellar vesicles (~60 nm) is composed of hydrogenated
soy phosphatidylcholine (PC), cholesterol, and pegylated lipid (DSPE-PEG).
Finally, AZD2811, a nanoparticle suspension containing Barasertib, is currently in a clinical trial for
the treatment of AML. Barasertib is the prodrug of the pyrazoloquinazoline Aurora kinase B inhibitor.
Aurora kinase B is overexpressed in tumor cells; its inhibition results in the disruption of spindle
checkpoint functions and chromosome alignment, thus affecting cell division and proliferation and
selectively inducing apoptosis [180]. Targeting Aurora B kinase with AZD2811 nanoparticles is a novel
approach to deliver a cell-cycle inhibitor in AML and has a potential to improve the clinical activity
seen with cell-cycle agents in this disease. In this system, the drug is encapsulated into nanosystems,
known as accurins, composed of block copolymers of poly-d,l-lactide (PLA) and poly(ethylene glycol)
(PEG)—both clinically validated biomaterials with a long history of safe use in humans [181]. Various
accurins formulations have been tested during preclinical assays, in order to maximize the Barasertib
encapsulation efficiency and the control of drug release. Finally, thanks to the improved preclinical
efficacy and tolerability data displayed by the pamoic acid lead formulation, it has been selected for
clinical evaluation [182].
7. Conclusions
Currently, the treatment of leukemia appears to be one of the most important medical areas of
testing at chemical level nanosized systems for drug delivery. The investigated systems that entered
the clinical trials are essentially represented by liposomes as they provide a prolonged lifetime of the
drug in the systemic circulation coupled with a slow steady release of their content. The latter property
is particularly important in the treatment of leukemia as the combination of drugs having different
effects on the targeted cells is of paramount importance. It is well established that the maintenance
of proper molecular ratios between the administrated drugs at the site of action is crucial for the
success of the therapy. The slow release of the payload from the liposomal carriers guarantees the
availability of the administered drugs in the proper, intended ratio. However, one may expect the
other systems will provide peculiar properties that may further improve the treatment of leukemia.
Certainly, the introduction of targeting vectors that selectively deliver the nanosized system to the
selected cell is a route that needs further development. Then it appears that a combination strategy
with some newly approved agents (such as kinase inhibitors or BCL2 inhibitors) and selective targeting
by functionalized nanoparticles may open up important opportunities to cure more patients suffering
from AML, ALL, and CLL.
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